This is a working overview of IRAP, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Only promethium-147 has uses outside laboratories. It is obtained as the oxide or chloride, in milligram quantities. This isotope has a relatively long half-life and its radiation has a relatively small penetration depth in matter. Some signal lights use a luminous paint containing a phosphor that absorbs the beta radiation emitted by promethium-147 and emits light. This isotope does not cause aging of the phosphor, as alpha emitters do, and therefore the light emission is stable for a few years. Originally, radium-226 was used for the purpose, but it was later replaced by promethium-147 and tritium (hydrogen-3). Promethium may be favored over tritium for nuclear safety. In atomic batteries, the beta particles emitted by promethium-147 are converted into electric current by sandwiching a small promethium source between two semiconductor plates. These batteries have a useful lifetime of about five years. The first promethium-based battery was assembled in 1964 and generated "a few milliwatts of power from a volume of about 2 cubic inches, including shielding". Promethium is also used to measure the thickness of materials by measuring the amount of radiation from a promethium source that passes through the sample. It has possible future uses in portable X-ray sources, and as auxiliary heat or power sources for space probes and satellites (although the alpha emitter plutonium-238 has become standard for most space-exploration-related uses).
=== Women of color === The war on drugs also plays a negative role in the lives of women of color. The number of black women imprisoned in the United States increased at a rate more than twice that of black men, over 64% from 1986 to 1991. During that same period, the percentage of females incarcerated for drug-related offenses more than doubled. In 1989, black and white women had similar levels of drug use during pregnancy. However, black women were 10 times as likely as white women to be reported to a child welfare agency for prenatal drug use. In 1997, of women in state prisons for drug-related crimes, forty-four percent were Hispanic, thirty-nine percent were black, and twenty-three percent were white, quite different from the racial make up shown in percentages of the United States as a whole. Statistics in England, Wales, and Canada are similar. Women of color who are implicated in drug crimes are "generally poor, uneducated, and unskilled; have impaired mental and physical health; are victims of physical and sexual abuse and mental cruelty; are single mothers with children; lack familial support; often have no prior convictions; and are convicted for a small quantity of drugs". Additionally, these women typically have an economic attachment to, or fear of, male drug traffickers, creating a power paradigm that sometimes forces their involvement in drug-related crimes. Though there are programs to help them, women of color are usually unable to take advantage of social welfare institutions in America due to regulations.
Evidence from the study of extant Japanese macaques, indicating that the initial shift from quadrupedalism to bipedalism in the hominin evolution might have involved a shift of the primary action of the gluteus medius without any required morphological change, is presented by Shitara et al. (2026). Sekhavati, Prang & Strait (2026) study the relationships between hominin foot morphology and environmental context throughout the evolutionary history of hominins, and link the emergence of hominin bipedalism to increases of aridity in Central and Eastern Africa. Carlson et al. (2026) determine relative limb strength in Australopithecus and early members of the genus Homo, interpreted as indicative of frequent arboreal behavior in Australopithecus, as well as indicative of departure of hominins from arboreality by ∼1.8 million years ago. Kurki & Wall-Scheffler (2026) study the variation of pelvic canal dimensions in extant humans and extinct hominins, finding no evidence of a single trajectory of evolution of hominin pelvic shape. Komza, Viola & Schroeder (2026) interpret the evolution of the morphology of hominin midfoot as affected by selection for bipedalism in the lateral side in early bipeds such as Ardipithecus ramidus and shaped by a broad range of evolutionary processes in later hominins.
After surgery, a woman is instructed to restrict her activities and monitor herself for signs of infection such as an elevated temperature, discharge with a foul odor, and consistent pain. Clinicians may recommend that sneezing, coughing, and constipation be avoided. Splinting the abdomen while coughing supports an incised area and decreases pain with coughing. This is accomplished by applying gentle pressure to the surgical site for bracing during a cough. Recurrent surgery on the pelvic organs may not be due to a failure of the surgery to correct the cystocele. Subsequent surgeries can be directly or indirectly related to the primary surgery. Prolapse can occur at a different site in the vagina. Further surgery after the initial repair can be to treat complications of mesh displacement, pain, or bleeding. Additional surgery may be needed to treat incontinence. One goal of surgical treatment is to restore the vagina and other pelvic organs to their anatomically normal positions. This may not be the most important outcome to the treated woman, who may only want symptom relief and to improve her quality of life. The International Urogynecological Association (IUGA) has recommended that the data collected regarding cystocele and pelvic organ repair success include the presence or absence of symptoms, satisfaction, and Quality of Life. Other measures of a successful outcome should include perioperative data, such as operative time and hospital stay. Standardized Healthcare Quality of Life should be part of the measure of a successful resolution of cystocele.
Dissimilatory denitrification is widely used in the removal of nitrate and nitrite from municipal wastewater. An excess of nitrate can lead to eutrophication of waterways into which treated water is released. Elevated nitrite levels in drinking water can lead to problems due to its toxicity. Denitrification converts both compounds into harmless nitrogen gas. Specific types of anaerobic respiration are also critical in bioremediation, which uses microorganisms to convert toxic chemicals into less-harmful molecules to clean up contaminated beaches, aquifers, lakes, and oceans. For example, toxic arsenate or selenate can be reduced to less toxic compounds by various anaerobic bacteria via anaerobic respiration. The reduction of chlorinated chemical pollutants, such as vinyl chloride and carbon tetrachloride, also occurs through anaerobic respiration. Anaerobic respiration is useful in generating electricity in microbial fuel cells, which employ bacteria that respire solid electron acceptors (such as oxidized iron) to transfer electrons from reduced compounds to an electrode. This process can simultaneously degrade organic carbon waste and generate electricity.
Sources: en.wikipedia.org
Harald Pedersen (born 1878 in Øster Hurup – died 1966) was a Danish engineer and industrialist who, together with his brother Thorvald Pedersen, co-founded the pharmaceutical company Novo Terapeutisk Laboratorium in 1925, predecessor of Novo Nordisk. Their work played a key role in the early Danish insulin industry.
Xanthoria parietina hosts a diverse array of lichenicolous fungi—fungi that live on lichens. As of 2017, at least 41 species of lichenicolous fungi have been reported on X. parietina, including both obligate parasites and facultative colonizers. Examples include Athelia arachnoidea, Catillaria nigroclavata, and Capronia suijae. While some of these fungi may be pathogenic, others colonize the lichen without causing obvious damage to the thallus. In some cases, multiple lichenicolous and saprotrophic fungi can form complex communities on decaying thalli of X. parietina. One study in Austria documented ten different fungal species simultaneously colonizing damaged lichen thalli. The most visually apparent was Xanthoriicola physciae, while the dematiaceous hyphomycete Cladosporium macrocarpum was the most abundant colonizer, covering large areas of the thallus and apothecia with dark cottony filaments. This fungus causes visible discoloration and unevenness of the apothecial discs before eventually destroying the lichen structure. Other notable parasites included Lichenoconium xanthoriae, Lichenodiplis poeltii, and Pyrenochaeta xanthoriae. The highly destructive Marchandiomyces aurantiacus forms distinctive pale orange crumbles on the lichen surface, ultimately shrinking the thallus to a bleached, fragile film that clings to the substrate before complete decay.
== Academic career == Over the course of his academic career at Harvard University and the Harvard Medical School, Verdine has elucidated the molecular mechanism of epigenetic DNA methylation and pathways by which certain genotoxic forms of DNA damage are surveilled in and eradicated from the genome. As a professor, Verdine introduced biological principles into organic chemistry courses and helped found two fields of science that meld basic research and new medicines discovery: chemical biology, which enlists chemistry to answer biological questions; and new modalities, which works to discover and develop novel structural classes of therapeutics. He has served as the Erving Professor of Chemistry in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology at Harvard University since 1988. In 2013, he stepped down from his tenured professorship at Harvard, taking a leave of absence in order to focus full-time on steering Warp Drive Bio as CEO while continuing to run his eponymous Verdine Laboratory at the Harvard University Department of Stem Cell & Regenerative Biology. The laboratory focused on research based in chemical biology, including synthetic biologics and genomic research,. He has since transitioned to a 'professor of the practice' position at Harvard.
== Reconstitution of the tablets == The cuneiform tablets confirming Amat-Mamu's inheritance were stored in the home of her uncle, Ikun-pī-Sîn. They were kept separate from the family archive so as not to suggest that the inheritance was part of the family estate. It is unknown why they were kept in her uncle's house, though such storage arrangements with family members were not uncommon. When they were lost, her father Sîn-ilî had a deposition taken from the uncle admitting to their loss. Amat-Mamu was forced to go to the court so the judges could authorize the creation of new tablets. The tablets that Belessunu received as a girl during her own adoption were not reconstituted, for her and her witnesses to that contract had already died. The court also ruled that should the previous tablets be found, they were still the sole property of Amat-Mamu. The sequence of events describing both the legal dispute and the tablets' loss was documented on the reconstituted tablet. The reconstitution meant that some details were lost and inconsistencies were introduced, primarily in the description of the fields. The tablet is dated to the 14th year of Samsu-iluna's rule, placing its creation around 1736 BC. It has been preserved and is designated by archeologists as CT 47.63. Amat-Mamu's story is listed on the tablet alongside that of Belessunu, including Belessunu's dedication as a nadītu and her adoption by her aunt. The tablet is used in the modern era as a reference to understand Babylonian property and inheritance law.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.